When we stratified our NASH cohort by disease severity (Supplemental Figure 2), our data were partially consistent with this report, in that the concentration of MLKL, but not RIP1 or RIP3, was higher in patients with NAS greater than or equal to 3 compared with those with NAS less than 3. This evidence concerns the gene MLKL and metabolic dysfunction-associated steatohepatitis.